Tipranavir: a protease inhibitor for multi-drug resistant HIV-1

This publication has 23 references indexed in Scilit:

• Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study
  BMJ, 2005
• Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group
  The Journal of Infectious Diseases, 2004
• Treatment for Adult HIV Infection
  JAMA, 2004
• Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment FailureA Randomized Trial
  JAMA, 2002
• Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe
  Archives of internal medicine (1960), 2000
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
  The Lancet, 1999
• Structure-based discovery of tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor
  Biopolymers, 1999
• Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class
  Journal of Medicinal Chemistry, 1998
• Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
  New England Journal of Medicine, 1998